Tofacitinib Effective In Helping Rheumatoid Arthritis Patients, Trial Results Find

Editor’s Choice
Main Category: Arthritis / Rheumatology
Article Date: 29 Apr 2011 – 11:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article



Patient / Public:not yet rated

Healthcare Prof:2 stars

2 (1 votes)

Article Opinions: 1 posts

Adding Tofacitinib to standard treatment has been shown to be more effective than standard rheumatoid arthritis treatment alone, according to top-line results of two Phase 3 Trials, pharmaceutical giant Pfizer announced. The company says results details will be presented at a future scientific meeting.

The two trials were called ORAL Standard and ORAL Step.

The Oral Standard 12-month trial involved 717 patients with moderate-severe rheumatoid arthritis (RA) symptoms who did not respond properly to methotrexate – they were randomly selected to receive either tofacitinib 5 or 10 mg twice a day, adalimumab 40 mg subcutaneously every two weeks or a placebo – in both cases the patient was also on standard methotrexate therapy. The study met all primary endpoints (main goals), demonstrating considerable changes compared to placebo in alleviating RA signs and symptoms.

The Oral Step 6-month trial involved 399 patients with moderate-severe RA who had not responded properly to a TNF inhibitor. They were randomly selected to receive either tofacitinib 5 or 10 mg twice a day or a placebo, – in both cases the patient was also on standard methotrexate therapy. This study also met all its primary endpoints.

Neither of the two trials reported any new safety signals. Safety and efficacy data regarding tofacitinib in both studies are no different from what was reported in previous studies.

Rheumatoid Arthritis

Rheumatoid arthritis, also known as rheumatoid disease is a long-lasting (chronic), disabling and progressive autoimmune disease. The patient experiences swelling and pain in the joints, inflammation and pain in the tissue surrounding joints, as well as other organs. In most cases, signs and symptoms appear initially in the hands and feet – however, any joint might be affected. Patients typically feel tired and generally unwell, and have stiff joints.

Rheumatoid arthritis is a systemic illness – it affects the whole body – often multiple organs may have symptoms. There may be fever, extreme fatigue, the inflammation can spread into the lungs and the pleura (membrane around the lungs, the pericardium and the sclera (the white outer coat of the eyeball). There may also be nodular lesions under the skin.

Rheumatoid arthritis is much more common in women than in men. It is much more common in smokers. The John Hopkins Arthritis Center, USA, says that about 1% to 2% of people worldwide are affected by RA. Nearly 5% of females aged at least 55 years have RA. In the USA, 70 people in every 100,000 has RA.

Industry experts say that Pfizer would like tofacitinib to become an oral alternative to existing injected or intravenous medications, including Humira (Abbot Laboratories). Tofacitinib could generate sales up to $2 billion. Pfizer hopes tofacitinib will make up for the expected loss in revenue when generic competition for Lipitor arrives at the end of this year.

Sources: Pfizer

Written by Christian Nordqvist


Copyright: Medical News Today

Not to be reproduced without permission of Medical News Today



Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

  Follow us on Twitter
news icon  Arthritis / Rheumatology headlines
email icon  email to a friend
printer icon  printer friendly version
newsletter icon  weekly newsletter
star icon  personalize your news

back to top - icon  back to top


Sulindac for RA

posted by Andrew on 29 Apr 2011 at 2:58 pm

I am a 66 year old male with RA and a family history of RA. My father had crippling RA of the hip. I have RA in the hands, feet and lower back.

I get complete relief from RA pain if I take 400 mg of Sulindac every 30 hours (to avoid itching). It has the added benefit of improving discomfort from COPD. It also significantly reduces risk of colon cancer, and research suggests, other cancers, too. I also have a family history of colon cancer. In addition, I also wear magnetic jewelry on my ankle, wrist and neck.

| post followup | alert a moderator |


Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

MediLexicon International Ltd Logo

Privacy Policy |
Terms and Conditions


MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.